February 8, 2024 /

Dyne Therapeutics — Advancing DYNE-251, an Investigational Medicine for DMD

Dyne Therapeutics joined PPMD for a community webinar on January 31, 2024. to present initial clinical data, released earlier this month, from the DELIVER trial of DYNE-251 in individuals with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Additionally, Dyne discussed its proprietary FORCE™ platform, driving efforts to develop targeted, modern oligonucleotide therapeutics while aiming to overcome limitations in delivery to muscle tissue, with the goal of stopping or reversing disease progression.

Posted on February 8, 2024

Join Our Mailing List